Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Angiodynamics (ANGO) Revenue (2016 - 2025)

Angiodynamics (ANGO) has disclosed Revenue for 16 consecutive years, with $79.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Revenue rose 9.04% year-over-year to $79.4 million, compared with a TTM value of $307.3 million through Nov 2025, up 7.26%, and an annual FY2025 reading of $292.5 million, down 3.76% over the prior year.
  • Revenue was $79.4 million for Q4 2025 at Angiodynamics, up from $75.7 million in the prior quarter.
  • Across five years, Revenue topped out at $91.1 million in Q2 2023 and bottomed at $67.5 million in Q3 2024.
  • Average Revenue over 5 years is $77.7 million, with a median of $77.6 million recorded in 2021.
  • The sharpest move saw Revenue soared 31.73% in 2021, then fell 22.06% in 2024.
  • Year by year, Revenue stood at $78.3 million in 2021, then rose by 9.13% to $85.4 million in 2022, then dropped by 7.44% to $79.1 million in 2023, then fell by 7.88% to $72.8 million in 2024, then increased by 9.04% to $79.4 million in 2025.
  • Business Quant data shows Revenue for ANGO at $79.4 million in Q4 2025, $75.7 million in Q3 2025, and $80.2 million in Q2 2025.